MONISTAT Drug Patent Profile

Which patents cover Monistat, and when can generic versions of Monistat launch?

Monistat is a drug marketed by Janssen Pharma, Medtech Products, Personal Prods, and Insight Pharms. and is included in twelve NDAs.

The generic ingredient in MONISTAT is miconazole nitrate. There are twenty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the miconazole nitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monistat

A generic version of MONISTAT was approved as miconazole nitrate by ACTAVIS PHARMA on November 19^th, 1993.

Summary for MONISTAT

US Patents:	0
Applicants:	4
NDAs:	12
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	1
DailyMed Link:	MONISTAT at DailyMed

Recent Clinical Trials for MONISTAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universidad Autonoma de San Luis Potosí	Phase 4
Hospital Central "Dr. Ignacio Morones Prieto"	Phase 4

See all MONISTAT clinical trials

US Patents and Regulatory Information for MONISTAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharma	MONISTAT	miconazole	INJECTABLE;INJECTION	018040-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Medtech Products	MONISTAT 3 COMBINATION PACK (PREFILLED)	miconazole nitrate	CREAM;TOPICAL, VAGINAL	021261-001	Feb 2, 2001		OTC	Yes	Yes
Medtech Products	MONISTAT 3	miconazole nitrate	SUPPOSITORY;VAGINAL	018888-001	Aug 15, 1984	AB	RX	Yes	Yes
Insight Pharms	MONISTAT-DERM	miconazole nitrate	CREAM;TOPICAL	017494-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Personal Prods	MONISTAT 5	miconazole nitrate	TAMPON;VAGINAL	018592-001	Oct 27, 1989		DISCN	No	No
Medtech Products	MONISTAT 1 COMBINATION PACK	miconazole nitrate	CREAM, INSERT;TOPICAL, VAGINAL	021308-001	Jun 29, 2001		OTC	Yes	Yes

Expired US Patents for MONISTAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharma	MONISTAT	miconazole	INJECTABLE;INJECTION	018040-001	Approved Prior to Jan 1, 1982
Janssen Pharma	MONISTAT	miconazole	INJECTABLE;INJECTION	018040-001	Approved Prior to Jan 1, 1982

International Patents for MONISTAT

See the table below for patents covering MONISTAT around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	974527	PROCEDIMENTO PER LA PRODUZIONE DI DERIVATI DELLO IMIDAZOL
Denmark	137947
Romania	56625
Japan	S51115
Germany	2063857
Ireland	33297	IMIDAZOLE DERIVATIVES

Market Dynamics and Financial Trajectory of MONISTAT

Last updated: March 15, 2026

What is the current market status for MONISTAT?

MONISTAT, a brand of antifungal medications primarily containing the active ingredient miconazole, operates fundamentally within the yeast and fungal infections segment. It remains a leading over-the-counter (OTC) topical treatment for vaginal candidiasis (yeast infections). The global antifungal market, including monistat, is projected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2022 to 2030, reaching an estimated $16.5 billion by 2030 [1].

How does MONISTAT position itself within the antifungal market?

MONISTAT holds a significant share of the OTC vaginal antifungal segment that is valued at approximately $1.2 billion globally in 2022 [2]. It benefits from broad consumer awareness, established distribution channels, and a reputation for efficacy.

Market Segment	Market Size (2022)	CAGR (2022-2030)	Key Competitors
OTC Vaginal Antifungals	$1.2 billion	4%	Monistat, Femigel, Gyne-Lotrimin
Prescription Antifungals	$2.8 billion	3.5%	Fluconazole, Itraconazole, Ketoconazole

What are the primary drivers influencing MONISTAT's demand?

1. Prevalence of Vaginal Candidiasis: An estimated 75% of women will experience at least one yeast infection during their lifetime, with recurrent cases in 5-8% of women [3].

2. OTC Accessibility: MONISTAT's OTC status removes the need for prescription, increasing consumer access and sales volume.

3. Public Awareness: Increased education about yeast infections and the availability of OTC remedies sustains steady demand.

4. Demographic Trends: Aging populations in developed economies expand the prevalence of vulvovaginal infections, albeit with some regional variance.

What are the competitive and regulatory considerations?

• Patent Status: MONISTAT originally held patent protections on formulation and delivery systems, many of which have expired, enabling generic competition.

• Generic Entry: Approximately 12 generic versions of miconazole-based products are available globally, exerting price pressure on MONISTAT.

• Regulatory Environment: Regulatory bodies like the FDA have consistent standards for OTC antifungal products. Recent policy shifts focus on improved formulation standards and labeling, with no significant barriers reported for continued sales.

How does MONISTAT's revenue trend compare historically?

• The brand generated approximately $350 million in retail sales globally in 2022, down from a peak of over $400 million in 2017, which aligns with increased generic competition.

• North America accounts for roughly 65% of MONISTAT's sales, with Europe contributing 20%, and the remainder spread across Asia-Pacific and Latin America.

What is the outlook for MONISTAT's financial trajectory?

• The global antifungal OTC market is expected to grow at 4% CAGR through 2030, which translates to incremental opportunities for MONISTAT, assuming stable brand recognition.

• Erosion in brand-exclusive revenue is anticipated due to generic competition; sales are projected to decline by 2-3% annually absent new formulation launches or indications.

• Investment in consumer marketing and potential reformulation for broader applications (e.g., oral, systemic) could mitigate revenue declines.

What strategic options exist for MONISTAT's future?

• Innovation: Developing new formulations, such as combination products or topical gels with longer duration.

• Expansion: Entering emerging markets with higher infection prevalence and lower OTC penetration.

• Brand Extension: Utilizing the MONISTAT brand for other antifungal or vaginal health products.

• Partnerships: Licensing or collaboration with regional distributors to strengthen market presence.

What financial risks should stakeholders consider?

• Increasing generic competition reduces the price premiums and sales volume.

• Regulatory changes could introduce new standards affecting formulations or labeling.

• Market saturation in established regions limits growth prospects without product innovation.

• Fluctuations in healthcare reimbursement policies could influence OTC sales patterns.

Summarized Financial Highlights

Metric	2022 Actual	2023-2025 Forecast	Notes
Retail Sales (Global)	$350 million	Declining 2-3% annually	Due to brand erosion and generic entry
Market Share (OTC Vaginal Antifungals)	Approx. 30%	Stable with slight decline	Competition-driven
Investment in Innovation	Variable	Increased focus	To preserve market share

Key Takeaways

• MONISTAT remains a leading product in OTC antifungal treatments but faces steady erosion from generics.

• Growing market size driven by infection prevalence offers incremental opportunities but is constrained by price competition.

• Strategic innovation and regional expansion are vital to offset declining revenues.

• Regulatory stability favors continued OTC sales, with no imminent policy threats identified.

• Stakeholders should monitor generic entrants, regulatory changes, and market trends to adapt strategies.

FAQs

1. Will MONISTAT regain market share through new formulations?
   Likely, if the formulations address unmet needs, such as longer-lasting effects or oral administration, but development lead times and regulatory approval processes are substantial.

2. What is the potential for entering developing markets?
   High infection prevalence and limited OTC antifungal products suggest growth potential; however, challenges include regulatory hurdles and distribution channels.

3. Are there any upcoming patent protections for MONISTAT?
   Most formulations are off-patent, but specific delivery mechanisms or combination formulations may still hold patent protections, providing limited exclusivity.

4. How does MONISTAT compare to prescription antifungals?
   Prescription antifungals generally have higher efficacy for recurrent or complicated cases but are less accessible; MONISTAT targets uncomplicated cases with high convenience.

5. Could innovation in systemic antifungal treatments impact MONISTAT?
   Potentially, systemic treatments can address broader infections but do not directly threaten topical treatments for uncomplicated yeast infections, which constitute most sales.

---

References

[1] MarketWatch. (2022). Global antifungal market forecast. Retrieved from https://www.marketwatch.com

[2] IBISWorld. (2022). OTC antifungal drug industry report.

[3] Centers for Disease Control and Prevention. (2021). Vulvovaginal candidiasis. Retrieved from https://www.cdc.gov